Resource Summary Report

Generated by NIF on Sep 8, 2026

NCI-H2228

RRID:CVCL_1543
Type: Cell Line

Proper Citation

RRID:CVCL_1543

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1543

Proper Citation: RRID:CVCL_1543

Description: Cell line NCI-H2228 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Lung adenocarcinoma

Defining Citation: PMID:8626706, PMID:8806092, PMID:11030152, PMID:18083107, PMID:18594010, PMID:20164919, PMID:20215515, PMID:22334442, PMID:22460905, PMID:22961666, PMID:23344087, PMID:24675041, PMID:25485619, PMID:25877200, PMID:26589293, PMID:27397505, PMID:28196595, PMID:29681454, PMID:30710758, PMID:30894373, PMID:31068700, PMID:31803961, PMID:31900393, PMID:31978347, PMID:35839778

Comments: Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H2228

Synonyms: H2228, H-2228, NCIH2228

Cross References: BTO:BTO_0006023, CLO:CLO_0008067, EFO:EFO_0002284, AddexBio:C0016017/4969, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-5935, BCRJ:0330, BioSample:SAMN03473167, BioSample:SAMN10987779,

cancercelllines:CVCL_1543, CCRID:3101HUMSCSP5001, Cell_Model_Passport:SIDM00729, ChEMBL-Cells:CHEMBL3308120, ChEMBL-Targets:CHEMBL1075536, CLS:305125, Cosmic:687816, Cosmic:897513, Cosmic:903617, Cosmic:930491, Cosmic:1146905, Cosmic:1609517, Cosmic:1612226, Cosmic:1995564, Cosmic-CLP:687816, DepMap:ACH-000447, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:687816, GEO:GSM434317, GEO:GSM513959, GEO:GSM514344, GEO:GSM794361, GEO:GSM827512, GEO:GSM887415, GEO:GSM888494, GEO:GSM1374727, GEO:GSM1670226, IARC_TP53:27190, IGRhCellID:NCIH2228, LiGeA:CCLE_800, LINCS_LDP:LCL-1652, PharmacoDB:NCIH2228_1081_2019, PRIDE:PXD011315, PRIDE:PXD030304, Progenetix:CVCL_1543, PubChem_Cell_line:CVCL_1543, Wikidata:Q54907944

ID: CVCL_1543

Record Creation Time: 20220427T220839+0000

Record Last Update: 20260905T181244+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H2228.

No alerts have been found for NCI-H2228.

Data and Source Information

Source: Cellosaurus

Usage and Citation Metrics

We found 41 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Zhao Y, et al. (2026) TOP2A, BUB1B, CENPF, KIF15 and MELK: Key senescence-related genes linked to prognosis and immune infiltration in lung adenocarcinoma. International journal of biological macromolecules, 335(Pt 1), 149215.

Pan K, et al. (2026) Lysine methylation-mediated SMYD2 degradation by casticin sensitizes non-small-cell lung cancer cells to osimertinib therapy. Biochemical pharmacology, 243(Pt 2), 117562.

Kahlhofer J, et al. (2025) TXNIP mediates LAT1/SLC7A5 endocytosis to limit amino acid uptake in cells entering quiescence. The EMBO journal, 44(23), 7119.

Sakai T, et al. (2025) Utility of CK8/18 in identifying circulating tumor cells derived from lesions in patients with non-small cell lung cancer. Translational lung cancer research, 14(6), 2100.

Jeong J, et al. (2025) NSD2 inhibitors rewire chromatin to treat lung and pancreatic cancers. Nature.

Cook AL, et al. (2025) Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape. eLife, 13.

Pulice JL, et al. (2025) Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. Molecular cell, 85(7), 1311.

Li Q, et al. (2025) CircPTK2 enhances non-small cell lung cancer proliferation by inhibiting cellular senescence through stabilizing NFYA and elevating FOXM1. British journal of pharmacology.

Sasaki M, et al. (2025) Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers. Cancer research communications, 5(1), 24.

Pan K, et al. (2025) ANP32A-mediated histone 3 K27 acetylation is essential for sotorasib activity in KRAS-mutant non-small cell lung cancer. The Journal of biological chemistry, 302(2), 111110.

Satpathy S, et al. (2025) Integrative analysis of lung adenocarcinoma across diverse ethnicities and exposures. Cancer cell, 43(9), 1731.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. Cancer cell, 43(8), 1530.

Daum AK, et al. (2025) Cancer-associated fibroblasts promote drug resistance in ALK-driven lung adenocarcinoma cells by upregulating lipid biosynthesis. Cancer & metabolism, 13(1), 28.

Park SM, et al. (2025) Integrative transcriptomic analysis identifies emetine as a promising candidate for overcoming acquired resistance to ALK inhibitors in lung cancer. Molecular oncology, 19(4), 1155.

Koh DI, et al. (2024) The Immune Suppressor IGSF1 as a Potential Target for Cancer Immunotherapy. Cancer immunology research, 12(4), 491.

Bagnyukova T, et al. (2024) Synergy of EGFR and AURKA Inhibitors in KRAS-mutated Non-small Cell Lung Cancers. Cancer research communications, 4(5), 1227.

Luukkainen MEK, et al. (2024) ALK Inhibitor and Chemotherapy Combinations in Models of ALK-Translocated NSCLC. Anticancer research, 44(7), 2805.

Pelos G, et al. (2024) Fast proliferating and slowly migrating non-small cell lung cancer cells are vulnerable to decitabine and retinoic acid combinatorial treatment. International journal of cancer, 154(6), 1029.

Ishibashi K, et al. (2024) Astrocyte-induced mGluR1 activates human lung cancer brain metastasis via glutamate-dependent stabilization of EGFR. Developmental cell, 59(5), 579.

Torres-Mart??nez S, et al. (2024) Soluble galectin-3 as a microenvironment-relevant immunoregulator with prognostic and predictive value in lung adenocarcinoma. Molecular

oncology, 18(1), 190.